Shares of ArQule, Inc. (NASDAQ:ARQL) hit a new 52-week high during trading on Thursday . The company traded as high as $1.69 and last traded at $1.67, with a volume of 93900 shares. The stock had previously closed at $1.67.

ARQL has been the subject of a number of research analyst reports. ValuEngine lowered shares of ArQule from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Zacks Investment Research lowered shares of ArQule from a “buy” rating to a “hold” rating in a research note on Wednesday, September 6th. Finally, Needham & Company LLC upgraded shares of ArQule from a “hold” rating to a “buy” rating in a research note on Thursday, December 14th.

The stock has a market capitalization of $145.47, a P/E ratio of -4.12 and a beta of 1.38. The company has a debt-to-equity ratio of 2.33, a current ratio of 3.45 and a quick ratio of 3.45.

ArQule (NASDAQ:ARQL) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02. During the same quarter in the prior year, the business earned ($0.08) earnings per share. research analysts anticipate that ArQule, Inc. will post -0.39 earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in ARQL. Northern Trust Corp grew its position in ArQule by 0.9% during the second quarter. Northern Trust Corp now owns 154,513 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 1,385 shares during the period. Curbstone Financial Management Corp grew its position in ArQule by 100.0% during the third quarter. Curbstone Financial Management Corp now owns 104,572 shares of the biotechnology company’s stock valued at $116,000 after buying an additional 52,286 shares during the period. First Eagle Investment Management LLC grew its position in ArQule by 5.0% during the third quarter. First Eagle Investment Management LLC now owns 12,438,996 shares of the biotechnology company’s stock valued at $13,807,000 after buying an additional 591,421 shares during the period. Finally, Point72 Asset Management L.P. bought a new stake in ArQule during the third quarter valued at approximately $2,220,000. Hedge funds and other institutional investors own 52.12% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.dailypolitical.com/2017/12/29/arqule-arql-reaches-new-52-week-high-at-1-69.html.

ArQule Company Profile

ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.

Receive News & Ratings for ArQule Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule and related companies with MarketBeat.com's FREE daily email newsletter.